2X Match My Gift
This National Cancer Survivors Month, your gift is matched to expand treatment options and bring more patients into survivorship through Project Cure CRC.



The PTCH1 gene is a tumor suppressor gene that contains the instructions for making the patched-1 protein. The gene encodes a member of the patched family of proteins and is a component of the hedgehog signaling pathway.

PTCH1 is altered in approximately 4 percent of colorectal cancer patients.
Some mutations are acquired during a person's lifetime and are present only in certain cells. These genetic changes, called somatic mutations, are not inherited.

Although there are no FDA approved therapies targeting PTCH1 mutations to date, there is a clinical trial investigating the efficacy of a potential treatment in cancer patients with PTCH1 Loss of Function mutations.
Understanding colon cancer sidedness is one more tool to help patients ask the right questions and advocate for the most effective treatment plan.

Biomarker testing can guide colorectal cancer treatment and improve outcomes. Learn how CLEAR for CRC is helping patients access this critical tool.

After a grim prognosis, biomarker testing revealed a targeted treatment option for John E. Learn how knowing your biomarkers can change what’s possible.